Drug Trial Radar · NCT04990284
eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.
Last checked: Nov 19, 2026Latest source record: Mar 12, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
106
Actual
Start
Nov 29, 2021
Primary completion
Apr 4, 2023
Study completion Apr 4, 2023
Sponsor
- Lead sponsor
- Bial - Portela C S.A.Industry
- Sponsor type
- Industry
- First posted
- Aug 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, parallel group, multicentre, multinational, prospective, open-label exploratory study in Parkinson's disease (PD) patients to evaluate the add-on efficacy of opicapone 50 mg or an extra dose of levodopa (L-DOPA) 100 mg as first strategy for the treatment of wearing-off.
Conditions
- Parkinson Disease
Interventions
OpicaponeDrug
50 mg hard capsules. Oral administration, once-daily at bedtime, at least 1 hour before or after L-DOPA/carbidopa or benserazide (L-DOPA/DDCI).
L-DOPA/DDCIDrug
L-DOPA/carbidopa or benserazide (L-DOPA/DDCI), 100/25 mg, oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Absolute OFF-time from baseline to end of studyTime frame: up to 7 weeks
- Proportion of patients with one hour or more reduction in Absolute OFF-time from baseline to end of study (OFF-time responders)Time frame: up to 7 weeks
- Change in Absolute ON-time from baseline to end of studyTime frame: up to 7 weeks
- Proportion of patients with one hour or more increase in Absolute ON-time from baseline to end of study (ON-time responders)Time frame: up to 7 weeks
- Change in Percentage OFF-time between baseline and end of studyTime frame: up to 7 weeks
- Change in Percentage ON-time between baseline and end of studyTime frame: up to 7 weeks
Locations
25 sites in 5 countries. Site status is shown where the registry gives one.
Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin
Berlin, Germany
Praxis Dr. med. Kirsten Hahn
Berlin, Germany
Universitaetsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Parkinson-Klinik Ortenau GmbH&Co KG
Wolfach, Baden-Wurttemberg, Germany
Klinik Haag i. OB
Haag in Oberbayern, Bavaria, Germany
Universitaetsklinikum Wuerzburg
Würzburg, Bavaria, Germany
Praxis Dr. Oehlwein
Gera, Thuringia, Germany
Asklepios Fachklinikum Stadtroda
Stadtroda, Thuringia, Germany
Fondazione IRCCS CA' Granda Ospedale Maggiore Policlinico
Milan, Italy
Azienda Ospedaliera Universitaria- Università degli Studi della Campania "Luigi Vanvitelli"
Naples, Italy
Azienda Ospedaliero Universitaria Pisana
Pisa, Italy
Azienda Ospedaliera Santa Maria di Terni
Terni, Italy
Hospital Beatriz Ângelo
Loures, Lisbon District, Portugal
CNS-Campus Neurologico Senior
Torres Vedras, Lisbon District, Portugal
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Ruber Internacional
Madrid, Spain
Complejo Hospitalario Universitario de Orense
Ourense, Spain
Hospital General Universitario de Elche
Elche, Alicante, Spain
Hospital de Sant Joan Despi Moises Broggi
Sant Joan Despí, Barcelona, Spain
Complejo Hospitalario Universitario A Coruña
A Coruña, La Coruña, Spain
Hospital Universitario Puerta de Hierro Majadahonda
Majadahonda, Madrid, Spain
Royal Devon and Exeter Hospital (Wonford)
Exeter, Devon, United Kingdom
University Hospitals Plymouth
Plymouth, Devon, United Kingdom
King's College Hospital
London, Greater London, United Kingdom
Newcastle University- Clinical Ageing Research Unit
Newcastle upon Tyne, Tyne & Wear, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.